$11.16
5.47% today
Nasdaq, Aug 25, 07:46 pm CET
ISIN
US03476J1079
Symbol
ELTX

Angion Biomedica Corp Stock price

$11.80
+2.48 26.61% 1M
+3.56 43.20% 6M
+6.70 131.37% YTD
+7.34 164.57% 1Y
-4.30 26.71% 3Y
-158.40 93.07% 5Y
-158.40 93.07% 10Y
-158.40 93.07% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.37 3.24%
ISIN
US03476J1079
Symbol
ELTX
Industry

Key metrics

Basic
Market capitalization
$192.8m
Enterprise Value
$180.0m
Net debt
positive
Cash
$22.1m
Shares outstanding
16.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
105.4
Financial Health
Equity Ratio
-40.1%
Return on Equity
459.7%
ROCE
-227.7%
ROIC
-1,250.6%
Debt/Equity
5.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-43.5m | -
EBIT
$-44.6m | $-41.9m
Net Income
$-54.6m | $-44.6m
Free Cash Flow
$-35.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-7.6% | -
EBIT
-8.5% | 6.8%
Net Income
-40.6% | 14.2%
Free Cash Flow
2.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.4
FCF per Share
$-2.2
Short interest
4.0%
Employees
32
Rev per Employee
$0.0
Show more

Is Angion Biomedica Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Angion Biomedica Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Angion Biomedica Corp forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Angion Biomedica Corp forecast:

Buy
88%
Hold
13%

Financial data from Angion Biomedica Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
2% 2%
-
- Research and Development Expense 33 33
12% 12%
-
-43 -43
8% 8%
-
- Depreciation and Amortization 1.16 1.16
55% 55%
-
EBIT (Operating Income) EBIT -45 -45
8% 8%
-
Net Profit -55 -55
41% 41%
-

In millions USD.

Don't miss a Thing! We will send you all news about Angion Biomedica Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Angion Biomedica Corp Stock News

Neutral
GlobeNewsWire
13 days ago
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of follow-up data from the Phase 1 AMPLIFY-201 study evaluating ELI-002 in the peer-reviewed scientific journal, Nature Medicine. The artic...
Positive
The Motley Fool
18 days ago
Elicio (ELTX) Q2 Loss Beats Estimates
Neutral
GlobeNewsWire
18 days ago
Recent positive recommendation by the Independent Data Monitoring Committee (“IDMC”) to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis
More Angion Biomedica Corp News

Company Profile

Angion Biomedica Corp. operates as a biopharmaceutical company. It focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 06, 1998 and is headquartered in Uniondale, NY.

Head office United States
CEO Robert Connelly
Employees 32
Founded 2011
Website elicio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today